Source comparison
GH Secretion Profile Comparison
Both peptides produce pulsatile GH secretion — a rapid peak (approximately 20–30 minutes post-administration) followed by return toward baseline by 90–120 minutes. The key quantitative differences are: Peak GH amplitude: GHRP-2 > Ipamorelin by approximately 30
This comparison does not assign a generated winner or score.
- Both peptides produce pulsatile GH secretion — a rapid peak (approximately 20–30 minutes post-administration) followed by return toward baseline by 90–120 minutes. The key quantitative differences are:
- Peak GH amplitude: GHRP-2 > Ipamorelin by approximately 30–40% at equivalent molar doses across rodent and primate models. Area under the GH curve (AUC₀₋₁₂₀min): GHRP-2 shows approximately 1.3-fold higher GH AUC, reflecting both higher peak and marginally longer peak duration. IGF-1 response: both peptides produce proportional IGF-1 elevations approximately 8–12 hours post-injection; GHRP-2 produces correspondingly higher IGF-1 increments, but the magnitude difference narrows vs the GH difference due to hepatic GH receptor saturation effects at high GH concentrations.
- GHRH synergy: both peptides exhibit GHRH synergy (endogenous GHRH release from hypothalamic GHRH neurones via GHS-R1a activation amplifies pituitary GH response). The combined GHRH + GHRP-2 synergy is approximately 3.4–3.8-fold above either alone; GHRH + Ipamorelin synergy is approximately 3.0–3.2-fold — reflecting GHRP-2’s higher GHS-R1a affinity translating into marginally greater hypothalamic GHRH co-release.